Search Results

Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.

• Authors : Qin, Zhanzhong (AUTHOR); Chen, Linlin (AUTHOR); Liu, Min (AUTHOR)

Subjects: NATIONAL Institutes of Health (U.S.); TISSUE plasminogen activator; NIH Stroke Scale

• Source: Neurological Sciences. Jan2020, Vol. 41 Issue 1, p139-147. 9p. 1 Diagram, 3 Charts, 4 Graphs.

Record details

'Victor Babes' University of Medicine and Pharmacy Researchers Have Provided New Study Findings on Ischemia (Catheter-Directed Arterial Thrombolysis with a Low-Dose Recombinant Tissue Plasminogen Activator Regimen for Acute Lower Limb ...)

• Source: Hematology Week. December 9, 2024, 497

Record details

Stroke research priorities for the next decade--A representative view of the European scientific community.

• Authors : Meairs S; Neurologische Klinik, Ruprecht-Karls-Universitat Heidelberg, Theodor-Kutzer-Ufer, DE-68135 Mannheim (Germany). ; Wahlgren N

Subjects: Brain Ischemia/Brain Ischemia/Brain Ischemia/*drug therapy ; Fibrinolytic Agents/Fibrinolytic Agents/Fibrinolytic Agents/*therapeutic use ; Neuroprotective Agents/Neuroprotective Agents/Neuroprotective Agents/*therapeutic use

• Source: Cerebrovascular diseases (Basel, Switzerland) [Cerebrovasc Dis] 2006; Vol. 22 (2-3), pp. 75-82.Publisher: Karger Country of Publication: Switzerland NLM ID: 9100851 Publication Model: Print Cited Medium: Print ISSN: 1015-9770 (Print)

Record details

[ON THE DISAPPEARANCE OF THE TISSUE PLASMINOGEN ACTIVATOR ACTIVITY IN KIDNEY PRODUCED BY MITOMYCIN C ADMINISTRATION TO RABBITS].

• Authors : OKAMOTO U; TAKADA Y

Subjects: Enzyme Precursors* ; Fibrinolysin* ; Kidney*

• Source: Nihon seirigaku zasshi. Journal of the Physiological Society of Japan [Nihon Seirigaku Zasshi] 1964 Jun; Vol. 26, pp. 297-302.Publisher: Physiological Society of Japan Country of Publication: Japan NLM ID: 0417460 Publication Model: Print Cited Medium: Print ISSN:

Record details

From the Food and Drug Administration.

• Authors : Nightingale SL

Subjects: Ethics, Medical*; Cerebrovascular Disorders/Cerebrovascular Disorders/Cerebrovascular Disorders/*drug therapy ; Clinical Trials as Topic/Clinical Trials as Topic/Clinical Trials as Topic/*standards

• Source: JAMA [JAMA] 1996 Aug 14; Vol. 276 (6), pp. 443.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Print ISSN:

Record details

Agricola

Record details

Comprehensive analysis of the impact of procedure time and the 'golden hour' in subpopulations of stroke thrombectomy patients.

• Authors : Ash, Makenna; Dimisko, Laurie; Chalhoub, Reda M.

Subjects: INTRACRANIAL hemorrhage; SURGERY; PATIENTS

• Source: Journal of NeuroInterventional Surgery; Nov2024, Vol. 16 Issue 11, p1069-1075, 8p

Record details

Association of CACNA1C polymorphisms with serum BDNF levels in bipolar disorder.

• Authors : Smedler, Erik; Pålsson, Erik; Hashimoto, Kenji

Subjects: BIPOLAR disorder; TISSUE plasminogen activator; BRAIN-derived neurotrophic factor

• Source: British Journal of Psychiatry. Feb2021, Vol. 218 Issue 2, p77-79. 3p.

Record details

Researcher at Kyoto University Has Published New Data on Vitrectomy (Predictors of 3-month and 1-year visual outcomes after vitrectomy with subretinal tissue plasminogen activator injection for submacular hemorrhage)

• Source: Hematology Week. August 14, 2023, 1010

Record details

Research Results from Lomonosov Moscow State University Update Knowledge of Personalized Medicine (The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator)

• Source: Hematology Week. August 7, 2023, 4518

Record details